The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer
| Autor: | Georgia Robins Sadler, Matthew Marler, Vicky Jones, Joel E. Dimsdale, Christy J. Perez, Sherella Johnson, Paul J. Mills, Mairav Cohen-Zion, Sonia Ancoli-Israel, Barbara A. Parker, Karen A. Adler |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Vascular Endothelial Growth Factor A Cancer Research medicine.medical_specialty Time Factors Anthracycline Endothelium medicine.medical_treatment Breast Neoplasms Gastroenterology chemistry.chemical_compound Breast cancer Von Willebrand factor Internal medicine von Willebrand Factor medicine Humans Anthracyclines Neoplasm Metastasis Aged ICAM-1 Chemotherapy biology business.industry Interleukin-6 Middle Aged medicine.disease Intercellular Adhesion Molecule-1 Prognosis Vascular endothelial growth factor stomatognathic diseases Vascular endothelial growth factor A P-Selectin Endocrinology medicine.anatomical_structure Oncology chemistry Receptors Estrogen Lymphatic Metastasis biology.protein Disease Progression Female Endothelium Vascular business Receptors Progesterone |
| Zdroj: | Clinical cancer research : an official journal of the American Association for Cancer Research. 10(15) |
| ISSN: | 1078-0432 |
| Popis: | Purpose: The circulating soluble form of intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF) are elevated in women with breast cancer and associated with tumor progression and poor prognosis. This study examined the effects of anthracycline-based chemotherapy on plasma sICAM-1 and VEGF, as well as soluble P-selectin, von Willebrand factor, and interleukin-6 levels. Experimental Design: Twenty-six women diagnosed with stage I–IIIA breast cancer (mean age, 48.4 ± 10.4 years; range, 34–79 years) were studied before (week 1) and at weeks 2 and 3 of cycles 1 and 4 of chemotherapy. Results: The initial effect of chemotherapy was to reduce sICAM-1 levels; compared with pretreatment, sICAM-1 levels were decreased at week 2 of both cycles (P values < 0.01). sICAM-1 levels were elevated, however, at the start of cycle 4 as compared with pretreatment (P < 0.01). Chemotherapy led to an increase in sICAM-1 levels in node-positive but not node-negative patients (P < 0.01). VEGF levels were decreased at week 2 of cycle 4 (P = 0.001) and remained so at week 3. Similar to sICAM-1, VEGF levels were elevated at the start of cycle 4 as compared with pretreatment (P < 0.006). Soluble P-selectin levels decreased during week 2 of cycle 4 (P = 0.026). Neither interleukin-6 or von Willebrand factor were significantly changed in response to chemotherapy. Conclusions: The findings support prior studies suggesting that sICAM-1 levels derive from sources other than endothelial cells. In addition, whereas the more immediate effect of chemotherapy is to reduce sICAM-1 and VEGF, continued treatment may lead to significant elevations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|